EICHORPublic-registry site landscape for NCT05283486, “Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty”, a Sarcopenia study sponsored by TNF Pharmaceuticals, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05283486 (registry record) |
| Study title | Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty |
| Official title | A Double-blind, Randomized, Phase 2 Study to Investigate the Efficacy, Tolerability and Pharmacokinetics of MYMD1 in the Treatment of Participants Aged 65 Years or Older With Chronic Inflammation Associated With Sarcopenia/Frailty |
| Sponsor | TNF Pharmaceuticals, Inc. |
| Condition(s) | Sarcopenia; Frailty; Aging |
| Phase | PHASE2 |
| Listed sites | 3 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05283486.
Eichor generates a preliminary site-risk snapshot for NCT05283486 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Sarcopenia studies · Weekly briefs
